- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05041426
Letermovir for CMV Prevention After Lung Transplantation
An Open-label Pilot Protocol to Evaluate the Efficacy of Letermovir for the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Lung Transplant Recipients With Idiopathic Pulmonary Fibrosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Approximately 30 patients with IPF listed for lung transplantation will be enrolled and 15 are expected to undergo lung transplantation during the study period and receive the intervention. Patients who are CMV seropositive will receive letermovir for 6 months, patients who are CMV seronegative and receive lungs from a CMV seropositive donor (CMV D+/R-) will receive letermovir for 12 months. All patients will be followed for 12 weeks after completion of letermovir for the occurrence of CMV infection or disease after prophylaxis.
Historical controls will be LTRs for IPF from 2010-2019 who are CMV R+ or CMV D+/R- (donor positive/recipient negative). CMV prophylaxis in the historical controls was with valganciclovir for 6 months for CMV R+ and for 12 months for CMV D+/R-. Patients will be matched for CMV serostatus, induction immunosuppression, age, and telomere length.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Kailey Hughes Kramer, MPH
- Phone Number: 412-648-6453
- Email: hugheskl4@upmc.edu
Study Contact Backup
- Name: Fernanda Silveira, MD
- Phone Number: 412-648-6512
- Email: silvfd@upmc.edu
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- UPMC
-
Contact:
- Kailey Hughes Kramer, MPH
- Phone Number: 421-648-6453
- Email: hugheskl4@upmc.edu
-
Contact:
- Kelly Friday
- Phone Number: 412-648-6377
- Email: fridaykc@upmc.edu
-
Principal Investigator:
- Fernanda Silveira, MD
-
Pittsburgh, Pennsylvania, United States, 15213
- Not yet recruiting
- UPMC
-
Contact:
- Kailey Hughes Kramer, MPH
- Phone Number: 412-648-6453
- Email: hugheskl4@upmc.edu
-
Contact:
- Fernanda Silveira, MD
- Phone Number: 412-648-6512
- Email: silvfd@upmc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years on day of signing informed consent
- Listed for lung transplantation (single or double) due to a diagnosis of IPF or receipt of a lung transplant (single or double) for IPF in the 72 hours prior to enrollment
- Have a documented positive serostatus for CMV (CMV IgG seropositive, R+)
- Have a documented negative serostatus for CMV (CMV IgG seronegative, R-) and anticipate receiving or having received a lung allograft from a CMV IgG positive donor, D+). Only participants who are R+ or who are CMV D+/R- will receive intervention. Participants who are CMV D-/R- will be considered screen failures
- Able to travel to UPMC for routine post-transplant visits for a minimum of 15 months after transplantation
- Able to provide informed consent
- Be willing to use a contraceptive method while receiving LET and for at least 90 days following last dose of LET
Exclusion Criteria:
- Receipt of a previous solid organ transplant or hematopoietic stem cell transplant
- Multi-organ transplant recipient, i.e., heart-lung or lung-liver
- HIV seropositive
- HCV antibody or HCV RNA positive
- Donor HCV NAT positive
- Anticipated need for use of ganciclovir, valganciclovir, foscarnet, or cidofovir at the time of transplant
- Known or suspected hypersensitivity to LET or acyclovir
- CrCl < 10 ml/min or dialysis on day of transplant
- Child-Pugh Class C severe hepatic insufficiency
- Pregnancy or expected to conceive while on LET and through at least 90 days following cessation of LET
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Letermovir
Participants who are CMV seropositive (CMV R+) will receive letermovir prophylaxis for 6 months, and participants who are CMV donor seropositive/recipient seronegative (CMV D+/R-) will receive letermovir prophylaxis for 12 months.
Letermovir will be administered at a dose of 480 mg IV or oral once daily.
IV administration will occur only for those patients unable to swallow tablets.
If letermovir is co-administered with cyclosporine A, the dosage of letermovir will be decreased to 240 mg once daily.
|
Participants who are CMV R+ will receive LET prophylaxis for 6 months, and participants who are CMV D+/R- will receive LET prophylaxis for 12 months.
The duration of prophylaxis is per current standard of care.
LET will be administered at a dose of 480 mg IV or oral once daily.
IV administration will occur only for those patients unable to swallow tablets.
If LET is co-administered with cyclosporin A (CsA), the dosage of LET should be decreased to 240 mg once daily.
All patients will be followed for 12 weeks after completion of LET for the occurrence of CMV infection or disease after prophylaxis.
Participants on this protocol will receive acyclovir 400 mg orally BID for the duration of LET therapy for herpes simplex virus and varicella zoster virus prophylaxis.
Other Names:
|
Active Comparator: Valganciclovir
Historical controls will be lung transplant recipients for idiopathic pulmonary fibrosis from 2010-2019 who are CMV R+ or CMV D+/R-.
CMV prophylaxis in the historical controls was with valganciclovir for 6 months for CMV R+ and for 12 months for CMV D+/R-.
|
Historical controls will have received CMV prophylaxis with valganciclovir for 6 months for CMV R+ and for 12 months for CMV D+/R-.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of CMV infection or disease during prophylaxis
Time Frame: 6-12 months post-transplant
|
Proportion of lung transplant recipients with idiopathic pulmonary fibrosis with CMV infection or disease during letermovir prophylaxis.
This will be compared to the proportion of CMV infection or disease in historical lung transplant recipients with idiopathic pulmonary fibrosis who received valganciclovir prophylaxis
|
6-12 months post-transplant
|
Occurrence of CMV infection or disease in the 3 months following completion of prophylaxis
Time Frame: 12 weeks after completion of letermovir
|
Proportion of lung transplant recipients with idiopathic pulmonary fibrosis with CMV infection or disease in the 3 months following completion of prophylaxis with letermovir.
This will be compared to the proportion of CMV infection or disease in the 3 months following in historical lung transplant recipients with idiopathic pulmonary fibrosis who received valganciclovir prophylaxis.
|
12 weeks after completion of letermovir
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Discontinuation events
Time Frame: 6-12 months
|
Discontinuation of letermovir will be compared to discontinuation of valganciclovir in historical controls
|
6-12 months
|
Occurrence of leukopenia or neutropenia while on prophylaxis
Time Frame: 6-12 months
|
Proportion of participants who develop any of the following while receiving letermovir: total WBC count ≤ 3,500 cells/mL or absolute neutrophil count ≤ 1,000 cells/mL.
This will be compared to the rate of total WBC count ≤ 3,500 cells/mL or absolute neutrophil count ≤ 1,000 cells/mL in historical controls while receiving valganciclovir prophylaxis.
|
6-12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Fernanda Silveira, University of Pittsburgh
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY21040074
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CMV
-
St George's, University of LondonSt George's University Hospitals NHS Foundation TrustCompletedCMV | Congenital Cmv | Maternal Infections Affecting Fetus or Newborn | Shedding VirusUnited Kingdom
-
Grupo Espanol de trasplantes hematopoyeticos y...Not yet recruiting
-
QIAGEN Gaithersburg, IncTerminated
-
Medical University of South CarolinaTakedaRecruitingCMV | Transplant ComplicationUnited States
-
Meridian Bioscience, Inc.Completed
-
University Hospital, LimogesUniversity Hospital, LilleCompleted
-
Imperial College LondonWithdrawnAllogeneic Stem Cell Transplantation | CMV Reactivation | Autologous CMV Specific CD8+ T CellsUnited Kingdom
-
Virginia Commonwealth UniversityMerck Sharp & Dohme LLCRecruitingCMV | Kidney Transplant; ComplicationsUnited States
-
Fundación para la Investigación del Hospital Clínico...Completed
Clinical Trials on Letermovir
-
The First Affiliated Hospital of Soochow UniversityRecruitingHematopoietic Stem Cell Transplantation | CMV InfectionChina
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus (CMV) InfectionUnited States, Australia, Colombia, France, Germany, Israel, Japan, Mexico, Poland, Spain, Turkey
-
National Institute of Allergy and Infectious Diseases...Merck Sharp & Dohme LLCCompletedHIV Infections | Cytomegalovirus | CMVUnited States
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus Infection | Cytomegalovirus DiseaseJapan
-
University Medical Centre LjubljanaRecruiting
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingCytomegalovirus InfectionFrance
-
Memorial Sloan Kettering Cancer CenterMerck Sharp & Dohme LLCRecruitingCMV | CMV Infection | Hematopoietic Cell TransplantUnited States
-
University of PennsylvaniaMerck Sharp & Dohme LLCRecruitingCytomegalovirus Infections | Transplant-Related DisorderUnited States
-
Virginia Commonwealth UniversityMerck Sharp & Dohme LLCRecruitingCMV | Kidney Transplant; ComplicationsUnited States
-
Maimónides Biomedical Research Institute of CórdobaMERCK SHARP & DOHME DE ESPAÑA S.A.Not yet recruitingInfections, CytomegalovirusSpain